Tarsus Pharmaceuticals (TARS) FCF Margin (2021 - 2026)

Tarsus Pharmaceuticals' FCF Margin history runs 6 years deep, the most recent figure standing at 15.77% for Q1 2026.

• In Q1 2026, FCF Margin rose 1134.0% year-over-year to 15.77%; the TTM figure through Mar 2026 stood at 4.98% (up 2407.0% YoY), while the FY2025 annual figure was 4.94%, up 4130.0% from the prior year.
• FCF Margin for Q1 2026 stood at 15.77%, down from 7.23% in the prior quarter.
• The five-year high for FCF Margin was 15.46% in Q3 2025, with the low at 2865.86% in Q1 2022.
• The 5-year median for FCF Margin is 33.42% (2024), against an average of 416.61%.
• Peak annual rise in FCF Margin reached 332891 bps in 2022, while the deepest fall reached 282683 bps in 2022.
• Tarsus Pharmaceuticals' FCF Margin stood at 110.14% in 2022, then sank by 168 bps to 294.82% in 2023, then jumped by 88 bps to 35.67% in 2024, then jumped by 120 bps to 7.23% in 2025, then plunged by 318 bps to 15.77% in 2026.
• Business Quant data shows TARS's FCF Margin at 15.77% in Q1 2026, 7.23% in Q4 2025, and 15.46% in Q3 2025.